Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Donanemab could be the second amyloid antibody drug approved to treat early-stage Alzheimer’s disease. The drug slowed ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
There isn’t a cure for Alzheimer’s disease, the most common form of dementia in the U.S., but a third treatment for the ...
A U.S. Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug ...
A committee of independent advisers to the Food and Drug Administration voted unanimously Monday that the benefits outweigh ...
Charles Fuschillo, the Alzheimer’s Foundation of America president and CEO, says the latest drug, Donanemab, shows evidence ...
The new weight-loss drug company emerged from stealth with big plans to take on obesity drugs like Wegovy and Zepbound.
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...